O’Sullivan, J. M.
Taylor, J.
Gerds, A. http://orcid.org/0000-0002-3422-1309
Buckley, S.
Harrison, C. N.
Oh, S. http://orcid.org/0000-0002-8564-5400
List, A. F.
Howard, K. http://orcid.org/0000-0003-3335-4940
Dreau, H.
Hamblin, A.
Mead, A. J. http://orcid.org/0000-0001-8522-1002
Funding for this research was provided by:
RCUK | Medical Research Council (MR/l006340/1)
Article History
Received: 28 March 2023
Revised: 29 June 2023
Accepted: 6 September 2023
First Online: 20 October 2023
Competing interests
: AJM has consulted for Novartis, Bristol Myers Squibb/Celgene, and AbbVie, has received research funding from Novartis, Bristol Myers Squibb/Celgene, and CTI BioPharma, has received honoraria from Novartis and CTI BioPharma, and has served on the speaker’s bureau for Novartis. AG has acted in a consulting or advisory role for AbbVie, BMS, Constellation Pharmaceuticals, CTI BioPharma Corp., Novartis, PharmaEssentia, and Sierra Oncology. SB is employed by and holds stock in CTI BioPharma Corp. CNH has received honoraria from AbbVie, CTI BioPharma, Geron, Janssen, and Novartis; has served in consulting/advisory capacity for AOP, Celgene/ BMS, Constellation Pharmaceuticals, CTI BioPharma, Galecto, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra Oncology, and Novartis; has served on a speakers bureau for AbbVie, BMS, CTI BioPharma, Geron, Sierra Oncology, and Novartis; and has received research funding from BMS, Constellation Pharmaceuticals, and Novartis. STO has consulted for AbbVie, Blueprint Medicines, Celgene/BMS, Constellation Pharmaceuticals, CTI BioPharma, Disc Medicine, Geron, Incyte, and PharmaEssentia; and has received research funding from Actuate Therapeutics, Blueprint Medicines, Celgene/BMS, Constellation Pharmaceuticals, CTI BioPharma Corp., Incyte, Kartos Therapeutics, Sierra Oncology, and Takeda.